CL2011001485A1 - Compuestos heterociclicos nitrogenados sustituidos; inhibidor de proteinas anti-apoptoticas bc1-2; sus composiciones farmaceuticas; y su uso para tratar enfermedades causadas por un exceso de plaquetas, cancer de pulmon de celulas pequeñas, trombocitemia esencial, policitemia vera, restenosis. - Google Patents

Compuestos heterociclicos nitrogenados sustituidos; inhibidor de proteinas anti-apoptoticas bc1-2; sus composiciones farmaceuticas; y su uso para tratar enfermedades causadas por un exceso de plaquetas, cancer de pulmon de celulas pequeñas, trombocitemia esencial, policitemia vera, restenosis.

Info

Publication number
CL2011001485A1
CL2011001485A1 CL2011001485A CL2011001485A CL2011001485A1 CL 2011001485 A1 CL2011001485 A1 CL 2011001485A1 CL 2011001485 A CL2011001485 A CL 2011001485A CL 2011001485 A CL2011001485 A CL 2011001485A CL 2011001485 A1 CL2011001485 A1 CL 2011001485A1
Authority
CL
Chile
Prior art keywords
restenosis
platelets
excess
pharmaceutical compositions
lung cancer
Prior art date
Application number
CL2011001485A
Other languages
English (en)
Inventor
Jonathan Bayldon Baell
Chinh Thien Bui
Peter Colan
Peter Czabatar
Danettea Dudley
Wayne J Fairbrother
John Flygare
Original Assignee
Genentech Inc
Walter & Eliza Hall Inst Medical Res
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Walter & Eliza Hall Inst Medical Res, Abbvie Inc filed Critical Genentech Inc
Publication of CL2011001485A1 publication Critical patent/CL2011001485A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos heterocíclicos sustituidos; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar enfermedades tales como trombocitopenia esencial, policitemia vera, restenosis, cáncer, entre otras.
CL2011001485A 2008-12-19 2011-06-17 Compuestos heterociclicos nitrogenados sustituidos; inhibidor de proteinas anti-apoptoticas bc1-2; sus composiciones farmaceuticas; y su uso para tratar enfermedades causadas por un exceso de plaquetas, cancer de pulmon de celulas pequeñas, trombocitemia esencial, policitemia vera, restenosis. CL2011001485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13949208P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
CL2011001485A1 true CL2011001485A1 (es) 2012-02-24

Family

ID=42316723

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001485A CL2011001485A1 (es) 2008-12-19 2011-06-17 Compuestos heterociclicos nitrogenados sustituidos; inhibidor de proteinas anti-apoptoticas bc1-2; sus composiciones farmaceuticas; y su uso para tratar enfermedades causadas por un exceso de plaquetas, cancer de pulmon de celulas pequeñas, trombocitemia esencial, policitemia vera, restenosis.

Country Status (22)

Country Link
US (1) US8232273B2 (es)
EP (1) EP2373163B1 (es)
JP (1) JP5770102B2 (es)
KR (1) KR101685718B1 (es)
CN (1) CN102316733B (es)
AU (1) AU2009335843A1 (es)
BR (1) BRPI0918360A8 (es)
CA (1) CA2747170C (es)
CL (1) CL2011001485A1 (es)
CO (1) CO6390075A2 (es)
CR (1) CR20110388A (es)
DO (1) DOP2011000199A (es)
EC (1) ECSP11011213A (es)
ES (1) ES2544452T3 (es)
IL (1) IL213596A0 (es)
MX (1) MX2011006509A (es)
NZ (1) NZ593537A (es)
PE (1) PE20120334A1 (es)
RU (1) RU2525116C2 (es)
SG (1) SG172259A1 (es)
WO (1) WO2010080503A1 (es)
ZA (1) ZA201104467B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134685B1 (en) 2007-04-16 2015-09-02 AbbVie Inc. 7-nonsubstituted indole derivatives as mcl-1 inhibitors
ES2462715T3 (es) * 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2588748T3 (es) 2011-05-20 2016-11-04 Glaxosmithkline Intellectual Property (No. 2) Limited Nuevos compuestos como inhibidores de la diacilglicerol aciltransferasa
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP5955531B2 (ja) * 2011-11-07 2016-07-20 千葉県 抗癌剤
SG10201610416TA (en) 2012-06-13 2017-01-27 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
CN103515415A (zh) * 2012-06-26 2014-01-15 群康科技(深圳)有限公司 叠层结构与其制造方法、以及包含其的电子装置
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
MX360172B (es) * 2012-08-13 2018-10-12 Abbvie Inc Agentes que inducen la apoptosis.
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2623304T3 (es) 2012-10-11 2017-07-10 F. Hoffmann-La Roche Ag Azaindolinas
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2970277B1 (en) 2013-03-15 2021-07-28 Knopp Biosciences LLC Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG10201805670QA (en) 2014-01-28 2018-08-30 Buck Inst Res Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
FI3572405T3 (fi) 2014-09-12 2023-09-22 Knopp Biosciences Llc Benzoimidatsol-1,2-yyli amidit kv7 kanavan aktivaattoreina
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
BR112017012342A2 (pt) * 2014-12-09 2018-02-27 Abbvie Inc compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
RU2020123953A (ru) * 2014-12-09 2020-09-18 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2020004108A (es) 2015-02-20 2022-01-03 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
EP3285583B1 (en) 2015-04-20 2021-03-17 The Regents of The University of Michigan Small molecule inhibitors of mcl-1 and uses thereof
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
AU2016355303B2 (en) * 2015-11-20 2021-10-07 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
CA3018991A1 (en) 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN116284404A (zh) 2016-06-08 2023-06-23 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
JP7278208B2 (ja) * 2016-08-09 2023-05-19 ザ ユニバーシティ オブ ダラム 合成レチノイド（細胞の調節における）
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018092064A1 (en) * 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN108186642B (zh) * 2018-01-11 2019-11-08 广西师范大学 一种协同起作用治疗肺癌的药物组合物
WO2019144117A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
PL3755703T3 (pl) 2018-02-20 2022-11-07 Incyte Corporation Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
KR20200133259A (ko) 2018-03-19 2020-11-26 놉 바이오사이언시스 엘엘씨 Kv7 채널 활성화제 조성물 및 이의 사용 방법
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AR119494A1 (es) * 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CA3198996A1 (en) 2020-11-24 2022-06-02 Matthew T. Burger Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN114294905B (zh) * 2021-11-19 2023-04-25 中粮生物科技股份有限公司 利用红外或微波干燥聚羟基脂肪酸酯的方法
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2024036961A1 (zh) * 2022-08-19 2024-02-22 北京三秀生物医药科技有限公司 一种抗衰老相关疾病的前药及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718570A1 (de) * 1987-06-03 1988-12-15 Boehringer Ingelheim Kg Benzo- und thieno-3,4-dihydro-1- pyridinylessigsaeurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO2001072712A1 (en) * 2000-03-24 2001-10-04 Cor Therapeutics, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
CA2417156A1 (en) * 2000-08-01 2003-01-23 Ono Pharmaceutical Co., Ltd. 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient
AU2003249713A1 (en) * 2002-07-03 2004-01-23 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
CA2539546C (en) * 2003-09-23 2010-07-13 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2006020049A2 (en) * 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
CA2668255A1 (en) * 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
AU2007338793B2 (en) * 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
WO2008123963A1 (en) * 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
EP2134685B1 (en) * 2007-04-16 2015-09-02 AbbVie Inc. 7-nonsubstituted indole derivatives as mcl-1 inhibitors
KR101511074B1 (ko) * 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Ｍｃｌ-1 억제제
AR067585A1 (es) * 2007-07-19 2009-10-14 Schering Corp Compuestos heterociclicos de amidas como inhibidores de la proteincinasa
CN101842362A (zh) 2007-09-27 2010-09-22 沃尔特及伊莱萨霍尔医学研究院 苯并噻唑化合物
ES2462715T3 (es) * 2008-12-19 2014-05-26 Genentech, Inc. Compuestos y métodos de uso

Also Published As

Publication number Publication date
CN102316733A (zh) 2012-01-11
JP2012512891A (ja) 2012-06-07
BRPI0918360A2 (pt) 2017-10-10
KR20110102473A (ko) 2011-09-16
ZA201104467B (en) 2012-10-31
PE20120334A1 (es) 2012-04-16
CA2747170A1 (en) 2010-07-15
NZ593537A (en) 2013-07-26
ECSP11011213A (es) 2011-09-30
RU2011129776A (ru) 2013-01-27
RU2525116C2 (ru) 2014-08-10
CA2747170C (en) 2017-07-18
US8232273B2 (en) 2012-07-31
WO2010080503A1 (en) 2010-07-15
CO6390075A2 (es) 2012-02-29
AU2009335843A1 (en) 2011-07-21
EP2373163A1 (en) 2011-10-12
CR20110388A (es) 2011-09-09
DOP2011000199A (es) 2011-10-15
ES2544452T3 (es) 2015-08-31
EP2373163A4 (en) 2012-10-24
KR101685718B1 (ko) 2016-12-12
US20100210622A1 (en) 2010-08-19
SG172259A1 (en) 2011-07-28
EP2373163B1 (en) 2015-06-10
BRPI0918360A8 (pt) 2017-12-05
MX2011006509A (es) 2011-10-19
JP5770102B2 (ja) 2015-08-26
IL213596A0 (en) 2011-07-31
CN102316733B (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
CL2011001485A1 (es) Compuestos heterociclicos nitrogenados sustituidos; inhibidor de proteinas anti-apoptoticas bc1-2; sus composiciones farmaceuticas; y su uso para tratar enfermedades causadas por un exceso de plaquetas, cancer de pulmon de celulas pequeñas, trombocitemia esencial, policitemia vera, restenosis.
ECSP11011183A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
GT200500237A (es) Derivados de pirimidina
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
SV2011003855A (es) Heteroarilos sustituidos
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
UY32918A (es) Nuevos compuestos de 2-piridona
CR20120031A (es) Derivados de 5-fluoropirimidinona
BRPI0911208A2 (pt) moduladores inflamatórios antioxidantes: ácido oleanólico derivados com saturação no c-anel.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY30748A1 (es) Compuesto0s novedosos
CR11850A (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos
ECSP10010129A (es) Inhibidores de quinasas símil polo
CL2011001972A1 (es) Compuestos derivados de pirimidina fusionada, inhibidores akt; proceso de preparacion de dichos compuestos y compuestos intermediarios; compuestos intermediarios; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende y sus usos en el tratamiento de enfermedades hiperproliferativas.
UY32077A (es) Inhibidores de quinasa tipo polo
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.